1-4 of 4
black box warning
Close
Sort by
Journal Articles

Darbepoetin Hits a Double As Epoetin Hits a Home Run in Response to the 2007 FDA Black Box Warning

Virginia Noxon, Charles L. Bennett, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2075.
https://doi.org/10.1182/blood.V126.23.2075.2075
Published: 2015
Journal Articles

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

Virginia Noxon, Charles L Bennett, MD PhD MPP, Jun Wu
Journal: Blood
Blood (2014) 124 (21): 1276.
https://doi.org/10.1182/blood.V124.21.1276.1276
Published: 2014
Journal Articles

A Retrospective Review of Erythrocyte Stimulating Agents (ESA) Usage in Pharmacy Claims Data.

Scott A Lust, RPh, Milayna Subar, MD, Richard Faris, PhD, DPh, Wenlong Lin, MS, S. Jay Weaver, PharmD, MPH, Lorraine Tully, RHIT
Journal: Blood
Blood (2009) 114 (22): 900.
https://doi.org/10.1182/blood.V114.22.900.900
Published: 2009
Journal Articles

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Nina Undevia, MD MPH, Cara C. Tigue, BA, Dennis P. West, PhD, June M. McKoy, MD MPH JD, Beatrice J. Edwards, MD, David A. Dorr, MD MS, Dennis W. Raisch, RPh PhD, Charles L. Bennett, MD, PhD, MPP
Journal: Blood
Blood (2007) 110 (11): 3339.
https://doi.org/10.1182/blood.V110.11.3339.3339
Published: 2007